Fusion Antibodies to develop flagship platform after raising €1.4m in share placing

Fusion Antibodies to develop flagship platform after raising €1.4m in share placing

Belfast-based contract research firm’s Optimal platform is designed to capture the entire human antibody repertoire

Biotech Maxion Therapeutics scores £58m round to tackle inflammatory disease

Maxion Therapeutics, a Cambridge biotech firm developing treatments for inflammatory diseases, has closed a £58m Series A round.  The company is developing antibody-based drugs called KnotBodies, which are designed to overcome the challenges of targeting ion channels and G protein-coupled receptors (GPCRs).  Maxion’s drugs will target a broad range of inflammatory diseases including atopic dermatitis and inflammatory bowel disease. The firm is a…

Cambridge BioTech Maxion Therapeutics raises £58m

BioTech Maxion Therapeutics has raised a £58m Series A investment round to develop its technology and address large global markets. The Cambridge-based firm is currently developing antibody-based KnotBody drugs for ion channel and G protein coupled receptor (GPCR) driven diseases. Its lead KnotBody programme, MAX001, is currently in preclinical development to target inflammatory diseases such as bowel disease.  Other early-stage programmes inclu…

Press release - 17 March, 2025

British Patient Capital announces £10m investment in Maxion Therapeutics as part of £58m Series A Financing Round Rima Seth Mon, 03/17/2025 - 07:15 Content Typology Press release British Patient Capital announces £10m investment in Maxion Therapeutics as part of £58m Series A Financing Round Press release 17 March 2025 British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £10m investment in Maxion Therapeutic…

Lilly-backed UK biotech raises $72M to advance its antibody approach

Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates. The proceeds should give Maxion enough runway through the end of ...